Multiple strengths for your patients to help
manage moderate to moderately severe pain
Lortab is available as a solid white tablet.
LORTAB tablets should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen.
Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen containing product. The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.
Serious Skin Reactions: Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.
Misuse, Abuse, and Diversion of Opioids: LORTAB contains hydrocodone, an opioid agonist, and is a Schedule III controlled substance. LORTAB can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing LORTAB in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.
The most frequently reported adverse reactions include: lightheadedness, dizziness, sedation, nausea and vomiting.
Please see accompanying full prescribing information for additional important safety information and other product information.